Print | Need Larger Text?

Incident Report

Subform I: General Information

1. Report Type.

Update the report

Incident Report Number: 2007-8109

2. Registrant Information.

Registrant Reference Number: 110507-01 DTF

Registrant Name (Full Legal Name no abbreviations): Industry Task Force II on 2,4-D Research Data (members: Agro-Gor Corporation, Dow AgroSciences and Nufarm USA, Inc.)

Address: 1900 K Street, NW

City: Washington

Prov / State: DC

Country: USA

Postal Code: 200006-1108

3. Select the appropriate subform(s) for the incident.

Scientific Study

4. Date registrant was first informed of the incident.

5. Location of incident.

6. Date incident was first observed.

Product Description

7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.

PMRA Registration No.       PMRA Submission No.       EPA Registration No.

Product Name: 2,4-D Acid

• Active Ingredient(s)
  • 2,4-D (PRESENT AS ACID)

7. b) Type of formulation.

Application Information

8. Product was applied?

Unknown

9. Application Rate.

10. Site pesticide was applied to (select all that apply).

11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).

To be determined by Registrant

12. In your opinion, was the product used according to the label instructions?

Unknown

Subform VII: Scientific Study

1. Study Reference

Title 28-Day Inhalation Study with 2,4-D (preliminary results; test in progress)

Date 31-OCT-07

2. a) Is an extension needed to translate the document?

No

3. Type of incident identified in the study

Increased health or environmental risk

4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)

Study initiated in response to US EPA 2,4-D RED Data Call-In. Exposures + doses in study were: Nose-only (6 hrs/day, 5 days/week for 4 weeks); Five doses: 0.0, 0.05, 0.1, 0.3, 1.0 mg/L. Preliminary findings are that female body weights were reduced in the 1.0 mg/L dose group starting by day 14 and remained lower in the recovery group during the four week period following removal from the exposure. At the 0.3 and 1.0 mg/L dose levels, there were some effects noted in the clinical chemistry and hematology evaluations. There were indications of organ weight effects at the 1.0 mg/L dose level recovery group. Histopathological examination is incomplete at this time, and the study evaluation remains in progress.

5. a) Was the study discontinued before completion?

No

5. b) Provide the reason for discontinuation

6. If the study is ongoing, what is the expected completion date?

15-JAN-08

For Registrant use only

7. Provide supplemental information here

This is new preliminary information, and the Task Force has not defined if it is a risk. The final study will be submitted in early 2008.